HK1208880A1 - Method for producing monomeric and multimeric molecules and uses thereof - Google Patents

Method for producing monomeric and multimeric molecules and uses thereof

Info

Publication number
HK1208880A1
HK1208880A1 HK15109566.8A HK15109566A HK1208880A1 HK 1208880 A1 HK1208880 A1 HK 1208880A1 HK 15109566 A HK15109566 A HK 15109566A HK 1208880 A1 HK1208880 A1 HK 1208880A1
Authority
HK
Hong Kong
Prior art keywords
multimeric molecules
producing monomeric
monomeric
producing
multimeric
Prior art date
Application number
HK15109566.8A
Other languages
English (en)
Chinese (zh)
Inventor
Johannes Auer
Martin Bader
Stefan Dengl
Stefan Lorenz
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1208880A1 publication Critical patent/HK1208880A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
HK15109566.8A 2012-08-02 2015-09-29 Method for producing monomeric and multimeric molecules and uses thereof HK1208880A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179021 2012-08-02
PCT/EP2013/066096 WO2014020069A1 (fr) 2012-08-02 2013-07-31 Procédé de production de molécules monomères et multimères et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1208880A1 true HK1208880A1 (en) 2016-03-18

Family

ID=48914281

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109566.8A HK1208880A1 (en) 2012-08-02 2015-09-29 Method for producing monomeric and multimeric molecules and uses thereof

Country Status (13)

Country Link
US (3) US20150218250A1 (fr)
EP (1) EP2880169B1 (fr)
JP (1) JP6388581B2 (fr)
KR (1) KR20150037959A (fr)
CN (1) CN104508133B (fr)
BR (1) BR112015002091A2 (fr)
CA (1) CA2876099A1 (fr)
ES (1) ES2633894T3 (fr)
HK (1) HK1208880A1 (fr)
MX (1) MX2015000683A (fr)
RU (1) RU2015106812A (fr)
SG (1) SG11201408530YA (fr)
WO (1) WO2014020069A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
BR112017000689A2 (pt) 2014-07-15 2018-01-23 Astellas Pharma Inc. novo anticorpo tie-2 anti-humano
WO2016071377A1 (fr) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Variants de région fc présentant des propriétés modifiées de liaison à fcrn et à la protéine a
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
WO2017194593A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de nettoyage et/ou de désinfection d'une matrice de séparation
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2018025809A1 (fr) * 2016-08-01 2018-02-08 株式会社カネカ Adsorbant pour des particules de calciprotéine, système d'élimination par adsorption et son procédé d'utilisation
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US20190352363A1 (en) * 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3688036A4 (fr) 2017-09-25 2021-06-23 Dingfu Biotarget Co., Ltd Hétérodimère protéique et utilisation de celui-ci
KR20210005169A (ko) 2018-04-25 2021-01-13 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
AU2019366956A1 (en) 2018-10-23 2021-05-20 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
US11952411B2 (en) 2020-08-19 2024-04-09 Janssen Biotech, Inc. Materials and methods of using engineered ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
CA2338000C (fr) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives 4-thiomaleimidiques solubles dans l'eau et methodes pour les produire
CN1341121A (zh) * 1999-01-07 2002-03-20 利思进药品公司 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
HUP0303246A2 (hu) 2001-02-23 2003-12-29 Immunex Corporation Aktív fehérjék fokozott kinyerése
US7736657B2 (en) * 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
EP2027151A2 (fr) 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Compositions associées au cd47 et procédés destinés au traitement de maladies et de troubles immunologiques
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
WO2010048313A2 (fr) 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Fcrn recombinants et variants de celui-ci pour une purification de protéines de fusion contenant fc
EP2184070A1 (fr) 2008-11-07 2010-05-12 Hla-G Technologies Protéines HLA-G et leurs utilisations pharmaceutiques
ES2692268T3 (es) * 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
WO2012146630A1 (fr) * 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag Polypeptides acylés en position n-terminale, leurs procédés de préparation et leurs utilisations

Also Published As

Publication number Publication date
CA2876099A1 (fr) 2014-02-06
US11254728B2 (en) 2022-02-22
JP2015531591A (ja) 2015-11-05
US20170342128A1 (en) 2017-11-30
US20150218250A1 (en) 2015-08-06
JP6388581B2 (ja) 2018-09-12
EP2880169B1 (fr) 2017-05-17
CN104508133A (zh) 2015-04-08
WO2014020069A1 (fr) 2014-02-06
RU2015106812A (ru) 2016-09-27
US10570188B2 (en) 2020-02-25
US20200157183A1 (en) 2020-05-21
SG11201408530YA (en) 2015-03-30
BR112015002091A2 (pt) 2017-12-12
MX2015000683A (es) 2015-04-10
KR20150037959A (ko) 2015-04-08
CN104508133B (zh) 2018-04-20
EP2880169A1 (fr) 2015-06-10
ES2633894T3 (es) 2017-09-25

Similar Documents

Publication Publication Date Title
HK1208880A1 (en) Method for producing monomeric and multimeric molecules and uses thereof
IL281148A (en) New and used KIF5B-RET fusion compounds
HK1214831A1 (zh) 新型融合分子及其應用
HK1206041A1 (en) Methods and means for the production of ig-like molecules
HK1210189A1 (en) Method for the production and selection of molecules comprising at least two different entities and uses thereof
ZA201406671B (en) Multispecific antigen-binding molecules and uses thereof
EP2931319A4 (fr) Molécules d'acide nucléique modifiées et leurs utilisations
IL234234B (en) 2ang binding molecules
EP2814865A4 (fr) Procédé de fabrication d'un polymère et produit de polymère
EP2918694A4 (fr) Élément en acier et processus pour le produire
EP2871482A4 (fr) Micropuce et son procédé de production
ZA201503542B (en) Novel immunotherapeutic molecules and uses thereof
ZA201405063B (en) Sealed-edge mirror and method for production thereof
EP2925777A4 (fr) Procédés de purification par pseudo-bioaffinité à base de monolithe pour le facteur viii et leurs applications
GB201213778D0 (en) Process and dressng
GB201218715D0 (en) Novel method and products
GB201208146D0 (en) Method and product